enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Category:Antiparkinsonian agents - Wikipedia

    en.wikipedia.org/wiki/Category:Antiparkinsonian...

    Generally, drugs outlined within the ATC code N04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiparkinsonian agents .

  3. Dopamine agonist - Wikipedia

    en.wikipedia.org/wiki/Dopamine_agonist

    Dopamine agonists are mainly used in the treatment of Parkinson's disease. [2] The cause of Parkinson's is not fully known but genetic factors, for example specific genetic mutations, and environmental triggers have been linked to the disease. [4] In Parkinson's disease dopaminergic neurons that produce the neurotransmitter dopamine in the ...

  4. List of dopaminergic drugs - Wikipedia

    en.wikipedia.org/wiki/List_of_dopaminergic_drugs

    Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.

  5. Hope for Parkinson’s disease symptoms is found in ... - AOL

    www.aol.com/finance/hope-parkinson-disease...

    Parkinson’s disease, which is lifelong, progressive, and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the ...

  6. ATC code N04 - Wikipedia

    en.wikipedia.org/wiki/ATC_code_N04

    ATC code N04 Anti-parkinson drugs is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup N04 is part of the anatomical group N Nervous system. [4]

  7. XP-21279 - Wikipedia

    en.wikipedia.org/wiki/XP-21279

    XP-21279 is a sustained-release levodopa (L-DOPA) prodrug and hence a dopamine precursor and non-selective dopamine receptor agonist which was under development for the treatment of Parkinson's disease. [4] [1] [3] It is taken by mouth. [1] [2] [3]

  8. Tavapadon - Wikipedia

    en.wikipedia.org/wiki/Tavapadon

    Tavapadon (developmental code names CVL-751, PF-06649751) is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. [2] [3] [4] It is under development by Cerevel Therapeutics, which acquired tavapadon from Pfizer in 2018. [2]

  9. Dopamine therapy - Wikipedia

    en.wikipedia.org/wiki/Dopamine_therapy

    One dopamine precursor, Levodopa, was the first drug approved specifically for Parkinson's disease. [2] DRT increases dopamine in the brain to optimal levels in order to return motor skills, impulsivity, and decision making to normal function. [3] Although DRT can improve motor skills and decision making in patients with mild to severe ...